NCPC(SH:600812)2018-10-17 16:00Financial Performance - Net profit attributable to shareholders rose by 254.32% to CNY 76.93 million for the first nine months of the year[6]. - Operating revenue for the first nine months reached CNY 7.08 billion, reflecting a growth of 24.25% year-on-year[6]. - Basic earnings per share increased by 261.54% to CNY 0.047 per share[7]. - The weighted average return on net assets improved by 1.03 percentage points to 1.44%[7]. - The company reported a net profit of CNY 1,120,819,282.41, up from CNY 1,096,064,708.13, indicating a slight increase of 2.2%[25]. - The net profit for the first nine months of 2018 was ¥41,062,621.57, down 38.3% from ¥66,475,790.19 in the same period last year[30]. - The company reported a total comprehensive income of ¥17,654,030.37 for Q3 2018, compared to a loss of ¥11,215,327.17 in Q3 2017[29]. Assets and Liabilities - Total assets increased by 4.50% to CNY 17.92 billion compared to the end of the previous year[6]. - The total current assets reached ¥7,472,970,361.46, up from ¥6,817,511,894.92 at the beginning of the year[19]. - Current liabilities rose to CNY 10,383,352,891.15, up from CNY 8,695,175,013.01, indicating a 19.4% increase[20]. - Total liabilities reached CNY 12,497,183,088.91, compared to CNY 11,870,926,953.78, showing an increase of 5.3%[21]. - Owner's equity increased to CNY 5,426,339,566.06 from CNY 5,280,573,227.77, reflecting a growth of 2.8%[21]. Cash Flow - Net cash flow from operating activities surged by 675.40% to CNY 635.46 million compared to the same period last year[6]. - Cash received from sales of goods and services increased by 32.11% to ¥5,846,525,141.83, indicating improved cash flow management[13]. - The net cash flow from operating activities for the first nine months of 2018 was ¥564,441,066.37, compared to a negative cash flow of ¥78,453,855.85 in the same period last year, indicating a significant improvement[36]. - Total cash inflow from operating activities reached ¥3,393,040,818.34, up from ¥2,950,355,986.29 year-on-year, reflecting a growth of approximately 15%[36]. - The ending cash and cash equivalents balance was ¥460,552,520.25, down from ¥632,268,956.93 at the end of the previous year[37]. Shareholder Information - The total number of shareholders reached 82,716 by the end of the reporting period[8]. - The top three shareholders hold a combined 52.56% of the shares, with the largest being Jizhong Energy Group at 21.6%[8]. Expenses - Sales expenses surged by 121.77% to ¥1,864,428,164.31, attributed to adjustments in marketing strategies and increased promotional efforts[12]. - R&D expenses increased by 63.43% to ¥59,555,259.31, reflecting ongoing efforts in the consistency evaluation of generic drugs[12]. - Research and development expenses for Q3 2018 amounted to ¥19,444,233.53, an increase of 50.5% from ¥12,943,580.33 in the previous year[28]. - The company reported a significant increase in sales expenses, which totaled ¥641,533,842.48 for the first nine months, compared to ¥420,080,596.15 in the previous year, reflecting a 52.6% rise[30]. Government Support and Investments - The company reported government subsidies amounting to CNY 19.67 million during the reporting period[9]. - The company received tax refunds amounting to ¥70,444,723.36 during the first nine months, compared to ¥52,857,160.30 in the previous year[33]. - The total investment income for the first nine months was ¥31,904,867.21, down from ¥139,331,085.41 in the same period last year, a decrease of 77.2%[30]. Future Outlook - The company has not disclosed any new product developments or market expansion strategies in this report[10]. - The company plans to continue focusing on R&D and market expansion to drive future growth and profitability[28].